Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
A First-Time-In-Human study on GSK\'s therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed subjects under nucleo(s)tide treatment.
Epistemonikos ID: 37eb556bd8a72566270a28741ee687dd456510db
First added on: Mar 23, 2020